Web17 jul. 2008 · A case of severe congestive cardiac failure is presented, in a 47-year-old patient with myeloma who had no prior cardiac history, after receiving bortezomib. We present here a case of severe congestive cardiac failure, in a 47-year-old patient with myeloma who had no prior cardiac history, after receiving bortezomib. Bortezomib is a … WebThe build-up of amyloid protein is called an ‘amyloid deposit’. Deposits can occur in various organs or tissues and cause problems. Facts about AL amyloidosis. Amyloid can build up in the kidneys, heart, liver, spleen, nerves, or digestive system; Amyloid can affect two or more organs at the same time; AL amyloidosis does not affect the brain
Pericardial relapse of multiple myeloma
Web15 okt. 2009 · Furthermore, the QT interval should be carefully monitored in patients with myeloma-related cardiac pathology (AL amyloidosis and light chain deposition disease) who commonly receive antimicrobial agents associated with QT prolongation (antifungal triazoles and fluoroquinolones). Direct damage to the heart tissue is a potential short-term or long-term complication from anticancer therapy. Patients with myeloma are at higher risk if they have any of the following: 1. history of smoking 2. family history of heart disease in a first-degree male relative younger than 55 or female … Meer weergeven Myeloma patients are at risk for serious and potentially life-threatening venous thromboembolic events because of their disease, the … Meer weergeven lowest range shotgun destiny
[PDF] Acute severe cardiac failure in a myeloma patient due to ...
WebA 59-year-old female was admitted to Tsukuba University Hospital and diagnosed as IgA-lambda multiple myeloma (stage IIIA). No cardiovascular disorder with the exception of minor ischemic changes in ECG was revealed before treatment. Web28 mei 2024 · Introduction. There is a growing epidemic of cardiovascular disease (CVD) in cancer patients during and after cancer treatment. Improved cancer-related survival and the development of more targeted molecular therapies, in addition to the continued use of anthracycline chemotherapy, have resulted in a significant increase in both current and … WebCarfilzomib has improved survival in patients with relapsed/refractory multiple myeloma (RRMM), but it may exert cardiovascular adverse events (CVAEs). The aim of this study was to assess whether treatment with daratumumab may ameliorate carfilzomib-related toxicity. We prospectively evaluated 25 patients with RRMM who received either … janitorial supplies swift current